Loading…

Persistent and Emerging Pneumococcal Carriage Serotypes in a Rural Gambian Community After 10 Years of Pneumococcal Conjugate Vaccine Pressure

The continuing impact of pneumococcal conjugate vaccines (PCVs) in regions with high pneumococcal transmission is threatened by the persistence of vaccine serotypes (VTs) and the emergence of nonvaccine serotypes (NVTs). In 2016, we conducted a cross-sectional carriage survey (CSS5) in a community w...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2021-12, Vol.73 (11), p.e3825-e3835
Main Authors: Usuf, Effua, Bottomley, Christian, Gladstone, Rebecca, Bojang, Ebrima, Jawneh, Kaddijatou, Cox, Isatou, Jallow, Edrissa, Bojang, Abdoulie, Greenwood, Brian, Adegbola, Richard A, Bentley, Stephen D, Hill, Philip C, Roca, Anna
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The continuing impact of pneumococcal conjugate vaccines (PCVs) in regions with high pneumococcal transmission is threatened by the persistence of vaccine serotypes (VTs) and the emergence of nonvaccine serotypes (NVTs). In 2016, we conducted a cross-sectional carriage survey (CSS5) in a community where PCV7 was first introduced in 2006 during a cluster-randomized trial conducted before nationwide introduction of PCV7 (2009) and PCV13 (2011). We estimated prevalence of PCV13 VT and NVT by age and compared these with earlier surveys before (CSS0), during (CSS1-3), and after the trial but before PCV13 (CSS4). Genomic analysis was conducted for the nontypeable pneumococci. Prevalence of PCV13 VT carriage decreased during the 10 years between CSS0 and CSS5 across all age groups (67.6% to 13.5%, P < .001; 59.8% to 14.4%, P < .001; 43.1% to 17.9%, P < .001; and 24.0% to 5.1%, P < .001, in
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciaa856